Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Liam Smyth, MD FRCPath, Rena Buckstein, MD FRCPC, Pennell Nancy, BSc, Rashmi Weerasinghe, Matthew Cheung, MD MS, FRCP, Eugenia Piliotis, MD FRCP, MD, Kevin Imrie, MD, David Spaner, MD PhD, Marciano D. Reis, MD, Lisa Chodirker, MD, Zeina Ghorab, Violet ruth,nancy Milliken, Angela Boudreau, RN, BScN, MN, CON(C), Neil Berinstein, MD

Blood (2017) 130 (Supplement 1): 4069.

https://doi.org/10.1182/blood.V130.Suppl_1.4069.4069

Published: 2017

Journal Articles

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Neil L Berinstein, MD, Nancy M Pennell, BSc, Rashmi Weerasinghe, Matthew C. Cheung, MD SM, FRCPC, Eugenia Piliotis, MD FRCP, MD, Kevin R Imrie, MD, Mary-Anne Cussen, Rena Buckstein, MD, Zeina Ghorab, Ellen Miles, Marciano D. Reis, MD

Blood (2016) 128 (22): 1794.

https://doi.org/10.1182/blood.V128.22.1794.1794

Published: 2016

Journal Articles

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Tony Reiman, MD, Kerry J. Savage, MD MSc, Michael Crump, MD, Matthew Cheung, MD, David A. MacDonald, MD, Rena Buckstein, MD, Stephen Couban, MD, Eugenia Piliotis, MD, Kevin R Imrie, MD, David Spaner, MD PhD, Sudeep Shivakumar, MD, John Kuruvilla, MD, Diego Villa, Lois E. Shepherd, MD, Tanya Skamene, MD, Chad Winch, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 4162.

https://doi.org/10.1182/blood.V128.22.4162.4162

Published: 2016

Journal Articles

Rituximab Improves Overall Survival In Patients Treated With CODOX-M/IVAC For Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL: A Single Center Experience and Review Of The Literature

Anca Prica, MD, Ariella Pratzer, Matthew C Cheung, MD, Kim Thompson, Eugenia Piliotis, MD, Neil L Berinstein, MD, Kevin R. Imrie, MD, Rahim Pradhan, Anju Vyas, David Good, MD, Liying Zhang, PhD, Rena Buckstein, MD

Blood (2013) 122 (21): 5093.

https://doi.org/10.1182/blood.V122.21.5093.5093

Published: 2013

Journal Articles

Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab

Neil L Berinstein, MD, FRCPC, Nancy M Pennell, B Sc, Mary-Anne Cussen, RN, BScN, CCRP, Kevin R Imrie, MD, Eugenia Piliotis, MD, FRCPC, Rena Buckstein, MD, Zeina Ghorab, MD, Ellen Anne Miles, MSc, Alden E. Chesney, MD, Matthew Cheung, MD

Blood (2012) 120 (21): 3681.

https://doi.org/10.1182/blood.V120.21.3681.3681

Published: 2012

Journal Articles

Rituximab Resistant Follicular Lymphoma: Predictors of Rituximab Resistance, Incidence of Transformation and Prognosis

Lee Mozessohn, MD, Matthew Cheung, MD, FRCPC, Michael Crump, MD, FRCPC, Rena Buckstein, MD, FRCPC, Neil L Berinstein, MD, FRCPC, Kevin R. Imrie, MD, FRCPC, John Kuruvilla, MD, FRCPC, Eugenia Piliotis, MD, FRCPC, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 4981.

https://doi.org/10.1182/blood.V118.21.4981.4981

Published: 2011

Journal Articles

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

Nancy M Pennell, B Sc, Matthew Cheung, MD, MS, FRCP, Lisa K Hicks, MD, MSc, FRCPC, Eugenia Piliotis, MD, FRCPC, Kevin R Imrie, MD, Rena Buckstein, MD, FRCPC, Cindy Davidson, RN, Mary-Anne Cussen, RN, BScN, CCRP, Zeina Ghorab, MD, Alden Chesney, MD, FRCPC, Neil L Berinstein, MD, FRCPC

Blood (2011) 118 (21): 2701.

https://doi.org/10.1182/blood.V118.21.2701.2701

Published: 2011

Journal Articles

The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Sita Bhella, MD, Neil L Berinstein, MD, FRCPC, Nancy Pennell, BSc, Matthew Cheung, MD, FRCPC, Kevin R. Imrie, MD, FRCPC, Violet Miliken, Marciano D. Reis, MD, FRCPC, Alden Chesney, MD, FRCPC, David Good, MD, FRCPC, Lisa Hicks, MD, MSc, FRCPC, Eugenia Piliotis, MD, FRCPC, Michael Crump, MD, FRCPC, Rena Buckstein, MD, FRCPC

Blood (2010) 116 (21): 1357.

https://doi.org/10.1182/blood.V116.21.1357.1357

Published: 2010

Journal Articles

Transfusion Dependence and Low Hemoglobin Have the Greatest Impact On Quality of Life (QOL) in MDS Patients - a Tertiary Care Cross Sectional and Longitudinal Study.

Rena Buckstein, MD, Shabbir Alibhai, MD, Adam Lam, Liying Zhang, Alex Mamedov, Matthew C Cheung, MD, Jeannie Callum, MD, Eugenia Piliotis, MD, Janey Tsiao, MD, Yulia Lin, MD, Richard A. Wells, MD, DPhil

Blood (2009) 114 (22): 2500.

https://doi.org/10.1182/blood.V114.22.2500.2500

Published: 2009

Journal Articles

Rituximab Based Regimen May Decrease the Incidence of CNS Relapse in Patients with Diffuse Large B-Cell Lymphoma.

Mervat Mahrous Mohamed, MD, Rena Buckstein, MD, FRCPC, Eugenia Piliotis, MD, Matthew C Cheung, MD, Neil Berinstein, MD

Blood (2009) 114 (22): 4770.

https://doi.org/10.1182/blood.V114.22.4770.4770

Published: 2009

Journal Articles

Iron Overload and Haematopoiesis in MDS: Does Blood Transfusion Promote Progression to AML?

Lap Shu Alan Chan, Rena Buckstein, MD, Marciano D. Reis, MD, Alden Chesney, II, MD, Adam Lam, Matthew C Cheung, MD, Eugenia Piliotis, MD, Lilly Chunhong Gu, MD, PhD, Richard A. Wells, MD, DPhil

Blood (2008) 112 (11): 2685.

https://doi.org/10.1182/blood.V112.11.2685.2685

Published: 2008

Journal Articles

Comprehensiveness of Quality of Life Instruments in Capturing Concerns Related to Chemotherapy-Induced Neutropenia

Lathi A Nina, MSc, Pierre Isogai, BSc, Nicole Mittmann, PhD, Carlo DeAngelis, PharmD, Matthew Cheung, Knowles Sandra, Eugenia Piliotis, Neil Shear, Scott Walker

Blood (2008) 112 (11): 1311.

https://doi.org/10.1182/blood.V112.11.1311.1311

Published: 2008

Journal Articles

Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies

Nancy Pennell, Matthew Cheung, MD SM, FRCP, Lisa K Hicks, MD, MSc, Rena Buckstein, MD, FRCPC, Kevin R Imrie, MD, Eugenia Piliotis, MD, David Spaner, Zeina Ghorab, Marciano D. Reis, MD, Violet Milliken, Angela Boudreau, Neil Berinstein, MD

Blood (2008) 112 (11): 4351.

https://doi.org/10.1182/blood.V112.11.4351.4351

Published: 2008

Journal Articles

Sezary Syndrome and Combination Immunomodulatory Therapy: Improving Clinical Outcomes

Eugenia Piliotis, MD, Panayiota Govas, Kevin R Imrie, MD, Matthew C Cheung, MD, Neil Shear, Scott Walsh, MD, FRCPC, Cathy Fairlie, RN, David Barth, MD, FRCPC

Blood (2008) 112 (11): 4957.

https://doi.org/10.1182/blood.V112.11.4957.4957

Published: 2008

Journal Articles

Prolonged Clinical and Molecular Remissions Following High-Dose Therapy/Autologous Stem Cell Transplantation (HDT/ASCT) and Rituximab and Interferon-alpha Maintenance for Relapsed High-Risk Follicular Lymphoma.

Matthew C. Cheung, MD, Neil L. Berinstein, MD, Nancy Pennell, BSc, Lisa K. Hicks, MD, Kevin R. Imrie, MD, Eugenia Piliotis, MD, Violet Milliken, BSc, Marciano Reis, MD, Rena Buckstein, MD

Blood (2007) 110 (11): 1902.

https://doi.org/10.1182/blood.V110.11.1902.1902

Published: 2007

Journal Articles

The Potential for Lost Productivity and Daily Activity Impairment in Patients with Follicular (FL) and Other Indolent Non-Hodgkin’s Lymphoma (NHL).

Matthew C. Cheung, MD, Kevin R. Imrie, MD, Jessica Friedlich, Rena Buckstein, MD, Lisa K. Hicks, MD, Yael Zaretsky, MD, Brigette Hales, MSc, Eugenia Piliotis, MD, Nicole Mittmann, PhD

Blood (2006) 108 (11): 344.

https://doi.org/10.1182/blood.V108.11.344.344

Published: 2006

Journal Articles

Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.

Lisa Hicks, Rena Buckstein, Joy Mangel, Eugenia Piliotis, Kevin Imrie, Matthew C. Cheung, David E. Spaner, Marciano D. Reis, Zeina Ghorab, Violet Milliken, Nancy Pennell, Neil Berinstein

Blood (2006) 108 (11): 3067.

https://doi.org/10.1182/blood.V108.11.3067.3067

Published: 2006

NARROW

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Rituximab Improves Overall Survival In Patients Treated With CODOX-M/IVAC For Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL: A Single Center Experience and Review Of The Literature

Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab

Rituximab Resistant Follicular Lymphoma: Predictors of Rituximab Resistance, Incidence of Transformation and Prognosis

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Transfusion Dependence and Low Hemoglobin Have the Greatest Impact On Quality of Life (QOL) in MDS Patients - a Tertiary Care Cross Sectional and Longitudinal Study.

Rituximab Based Regimen May Decrease the Incidence of CNS Relapse in Patients with Diffuse Large B-Cell Lymphoma.

Iron Overload and Haematopoiesis in MDS: Does Blood Transfusion Promote Progression to AML?

Comprehensiveness of Quality of Life Instruments in Capturing Concerns Related to Chemotherapy-Induced Neutropenia

Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies

Sezary Syndrome and Combination Immunomodulatory Therapy: Improving Clinical Outcomes

Prolonged Clinical and Molecular Remissions Following High-Dose Therapy/Autologous Stem Cell Transplantation (HDT/ASCT) and Rituximab and Interferon-alpha Maintenance for Relapsed High-Risk Follicular Lymphoma.

The Potential for Lost Productivity and Daily Activity Impairment in Patients with Follicular (FL) and Other Indolent Non-Hodgkin’s Lymphoma (NHL).

Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only